

Clinical Quality Measures
2023 measurement year

Measure		Rating	Rate
Adolescent Depression	PHQ-9 Utilization*	Average	77.50%
	Follow-up at Six Months	Expected	42.90%
	Response at Six Months	Expected	11.20%
	Remission at Six Months	Expected	5.40%
	Follow-up at 12 Months	Expected	36.80%
	Response at 12 Months	Expected	10.50%
	Remission at 12 Months	Expected	3.00%
Adult Depression	PHQ-9 Utilization*	Below	58.60%
	Follow-up at Six Months	Below Expected	37.60%
	Response at Six Months	Below Expected	13.10%
	Remission at Six Months	Below Expected	6.00%
	Follow-up at 12 Months	Below Expected	38.20%
	Response at 12 Months	Below Expected	13.00%
	Remission at 12 Months	Below Expected	7.10%
Adolescent Mental Health and/or Depression Screening*		Below	78.90%
Colorectal Cancer Screening		Expected	67.50%
Optimal Asthma Control - Adults		Below Expected	27.80%
Optimal Asthma Control - Children		Below Expected	31.10%
Optimal Diabetes Care		Below Expected	38.70%
HbA1c Control		Below Expected	67.50%
BP Control		Above Expected	86.60%
Daily Aspirin Use		Below Expected	95.50%
Statin Use		Below Expected	81.30%
Tobacco-Free		Below Expected	79.10%
Optimal Vascular Care		Below Expected	43.10%
BP Control		Above Expected	86.20%
Daily Aspirin Use		Below Expected	73.20%
Statin Use		Below Expected	85.70%
Tobacco-Free		Below Expected	76.70%

- Medical group not assigned to measure, did not have results, or did not meet reporting threshold

*Measure not risk adjusted

Healthcare Effectiveness Data and Information Set (HEDIS) Measures

2023 measurement year

Measure	Rating	Rate
Avoidance of Antibiotic Treatment in Acute Bronchitis/Bronchiolitis	Above	71.40%
Breast Cancer Screening	Above	84.90%
Cervical Cancer Screening	Below	61.20%
Childhood Immunization Status (Combo 10)	Average	51.40%
Chlamydia Screening in Women	Below	30.00%
Controlling High Blood Pressure	Above	80.10%
Diabetes Eye Exam	Below	56.90%
Immunizations for Adolescents (Combo 2)	Average	38.90%
Follow-up Care for Children Prescribed ADHD Medication	Average	36.00%
Osteoporosis Management in Women Who Had a Fracture	Above	44.80%
Use of Spirometry Testing in the Assessment and Diagnosis of COPD	Average	30.20%

- Medical group not assigned to measure, did not have results, or did not meet reporting threshold

Ratings

Above: Medical group's actual rate is significantly above its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

Average: Medical group's actual rate is not statistically different than its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

Below: Medical group's actual rate is significantly below its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

Total Cost of Care

2023 measurement year

Population	Monthly Average Cost	Rating	Higher/Lower than Average
Overall	\$697	Average	-1.60%
Adults	\$823	Average	-0.90%
Pediatric	\$315	Lower than average	-7.70%